Epidemiology and Meningococcal Serogroup Distribution in the United States

No abstract is available for this paper.

• Publication year

  2010

• Venue

  La Clinica pediatrica

• Publication date

  2010-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0009922809347797PMID 20507868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

  2010cited by this paper
• Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.

  2010cited by this paper
• Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

  2010influential reference
• Immunity to an Investigational H. influenzae type b- N. meningitidis Serogroups C & Y Conjugate Vaccine Measured in a Serum Bactericidal Activity in an Assay Using Human Complement

  2008cited by this paper
• The Implications of Broad-Spectrum Antibiotic Use Among Young Children on the Epidemiology of Invasive Meningococcal Disease

  2008cited by this paper
• Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002–2006

  2008cited by this paper
• Trends in wheat-flour fortification with folic acid and iron--worldwide, 2004 and 2007.

  2008cited by this paper
• Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

  2008cited by this paper
• Burden of Meningococcal Disease in Infants - United States, 1996-2005

  2008cited by this paper
• Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2007cited by this paper
• Immunogenicity and Safety of a Combined Haemophilus influenzae type b - Neisseria meningitidis serogroups C and Y - tetanus toxoid conjugate (HibCY) candidate vaccine

  2007cited by this paper
• Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine.

  2007cited by this paper
• A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.

  2007cited by this paper
• No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales.

  2006cited by this paper
• Prospects for Vaccine Prevention of Meningococcal Infection

  2006influential reference
• Immunogenicity of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Against Serogroups A, C, Y, and W-135 (MCV-4) in 9 to 15-Month Olds

  2006cited by this paper
• Antigenic shift and increased incidence of meningococcal disease.

  2006cited by this paper
• Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada.

  2005cited by this paper
• Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus.

  2005cited by this paper
• Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients

  2005cited by this paper
• Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children

  2005cited by this paper
• Bacteremia in an Immunocompromised Patient Caused by a Commensal Neisseria meningitidis Strain Harboring the Capsule Null Locus (cnl)

  2004cited by this paper
• Summary of notifiable diseases--United States, 2001.

  2003cited by this paper
• Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine.

  2003cited by this paper
• Impact of meningococcal C conjugate vaccine in the UK.

  2002cited by this paper
• Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

  2002cited by this paper
• Laboratory-Acquired Meningococcal Disease—United States, 2000

  2002cited by this paper
• Laboratory-acquired meningococcal disease--United States, 2000.

  2002cited by this paper
• Many carried meningococci lack the genes required for capsule synthesis and transport.

  2002cited by this paper
• Update: assessment of risk for meningococcal disease associated with the Hajj 2001.

  2001cited by this paper
• Risk factors for meningococcal disease in college students.

  2001cited by this paper
• Invasive meningococcal disease in adolescents and young adults.

  2001cited by this paper
• Meningococcal disease.

  2001cited by this paper
• ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES. PREVENTION AND CONTROL OF INFLUENZA: RECOMMENDATIONS OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

  2000influential reference
• Interactions of pathogenic Neisseria with host cells. Is it possible to assemble the puzzle?

  1999cited by this paper
• Risk of meningococcal infection in college students.

  1999cited by this paper
• The changing epidemiology of meningococcal disease in the United States, 1992-1996.

  1999cited by this paper
• Protection against meningococcal serogroup ACYW disease in complement‐deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine

  1998cited by this paper
• Molecular divergence of the sia locus in different serogroups of Neisseria meningitidis expressing polysialic acid capsules

  1997cited by this paper
• Capsule switching of Neisseria meningitidis.

  1997cited by this paper
• Summary of Notifiable Diseases, United States.

  1997cited by this paper
• Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases.

  1996cited by this paper
• Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience.

  1996cited by this paper
• Epidemiology and prevention of meningococcal disease

  1995cited by this paper
• Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population

  1994cited by this paper
• Surveillance for diabetes mellitus--United States, 1980-1989; and Laboratory-based surveillance for meningococcal disease in selected areas--United States, 1989-1991

  1993influential reference
• Infectious diseases associated with complement deficiencies

  1991cited by this paper
• Molecular characterization and expression in Escherichia coli of the gene complex encoding the polysaccharide capsule of Neisseria meningitidis group B.

  1989cited by this paper
• The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica

  1987cited by this paper
• Group A meningococcal disease in skid rows: epidemiology and implications for control.

  1984cited by this paper
• Complications and sequelae of meningococcal infections in children.

  1981cited by this paper
• Postsplenectomy infection.

  1981cited by this paper
• Letter: Misleading discs.

  1974cited by this paper
• Meningococcal carriage in a population of "normal" families.

  1971cited by this paper
• HUMAN IMMUNITY TO THE MENINGOCOCCUS

  1969cited by this paper

• Demographic Features of Invasive Meningococcal Disease in Taiwan, 1993 to 2020, and Genetic Characteristics of Neisseria meningitidis Isolates, 2003 to 2020

  2022cites this paper
• Practice and Cases in Emergency Medicine Title

  2019cites this paper
• Symptomatic Vaginal Infection by Neisseria meningitidis Resulting in Meningitis with Septic Shock

  2019cites this paper
• Control of invasive meningococcal disease: is it achievable?

  2016cites this paper
• History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention

  2016cites this paper
• Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements.

  2016cites this paper
• Global incidence of serogroup B invasive meningococcal disease: a systematic review.

  2015cites this paper
• Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing.

  2014cites this paper
• Serogroup C meningococcal conjugate vaccines: immunogenicity, immune persistence and induction of immunological memory

  2014cites this paper
• The changing epidemiology of meningococcal disease in North America 1945–2010

  2013cites this paper
• Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

  2012cites this paper
• An unusual transmission event of Neisseria meningitidis serogroup W135 type 2a in a healthcare setting, England, 2012.

  2012cites this paper
• ST93-Queensland community-acquired meticillin-resistant Staphylococcus aureus clone in France: outbreak in a scout camp and sporadic cases, July to August 2012.

  2012cites this paper
• Quadrivalent meningococcal conjugated vaccine: a routine or selective vaccine in Europe?

  2012cites this paper
• Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.

  2012cites this paper
• The changing and dynamic epidemiology of meningococcal disease.

  2012cites this paper
• Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.

  2012cites this paper
• Increase of meningococcal serogroup Y cases in Europe: A reason for concern?

  2012cites this paper
• Emergence of Neisseria meningitidis W-135 in the context of other rare serogroups

  2012cites this paper
• Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y

  2011cites this paper
• Meningococcal disease: early recognition is vital to patient outcomes.

  2011cites this paper
• Infection and Drug Resistance Dovepress Critical Appraisal of a Quadrivalent Crm 197 Conjugate Vaccine against Meningococcal Serogroups A, C W-135 and Y (menveo ® ) in the Context of Treatment and Prevention of Invasive Disease

  year unknowncites this paper